Enhance Clinical Trial Screening and Improve Patient Matching Accuracy

Why It Matters

This advancement tackles long‑standing inefficiencies in patient‑trial matching, accelerating enrollment and lowering trial costs. Greater transparency also builds clinician trust, potentially increasing participation rates across studies.

Key Takeaways

• Paradigm Health combines structured data with LLMs for trial matching.
• Solution surfaces both inclusion and exclusion reasons for each patient.
• AI-driven natural language summaries reduce review time for coordinators.
• Transparent evidence view improves enrollment speed and reduces missed opportunities.

Pulse Analysis

Traditional patient‑trial matching has relied heavily on discrete, structured fields such as age, diagnosis codes, and lab results. While these data points are easy to query, they miss the nuanced clinical language embedded in physician notes, imaging reports, and pathology narratives. The result is a high rate of false‑positive or false‑negative eligibility lists, leading to slower enrollment, higher operational costs, and delayed access to potentially life‑saving therapies. Industry analysts estimate that inefficient matching can add up to 15% to overall trial expenses, prompting a search for smarter, data‑rich solutions.

Paradigm Health’s new platform addresses these gaps by integrating large language models (LLMs) with existing electronic health record (EHR) structures. The LLM parses unstructured text, extracts relevant clinical criteria, and aligns them with trial protocols, producing a ranked list of candidates. Crucially, the system generates natural‑language explanations for each inclusion or exclusion decision, allowing coordinators to verify rationale without digging through multiple screens. Early pilot programs report a 30% reduction in manual chart review time and a 20% increase in eligible patient identification, underscoring the operational impact of AI‑augmented matching.

The broader implication for the pharmaceutical and biotech sectors is a shift toward transparent, AI‑enabled trial design. As regulators and sponsors demand faster enrollment and clearer audit trails, solutions that combine accuracy with explainability will become standard. Adoption of LLM‑powered matching could also democratize trial access by surfacing patients in community hospitals who might otherwise be overlooked. In a competitive landscape where speed to market is paramount, technologies that streamline recruitment while maintaining compliance are poised to reshape clinical research workflows.